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Abstract The aim of this study was to determine if transdermal penetration of fenoterol, a b-agonist
drug, could be enhanced and controlled by formulation modiﬁcation and formulation of transder-
mal patches. Pre-formulation studies were performed to determine the feasibility of a transdermal
dosage form of fenoterol. Penetration of fenoterol was determined using the hairless guinea pig skin
with unjacketed Franz diffusion cell. Transdermal patches were formulated using drug in-adhesive
technique. Several enhancers were investigated for fenoterol skin penetration. Transcutol–oleic acid
co-solvent gives the highest drug ﬂux among all tested liquid formulations. Pretreatment of the skin
with oleic acid 2 h before patch application signiﬁcantly increases drug diffusion. Cis-oleic acid gives
best results compared to oleic acid. Azone derivative (1-dodecyl-2-pyrrolidinone) gives the highest
drug diffusion amongst all tested enhancers. Results of this study show the feasibility of using fen-
oterol formulated in transdermal delivery system in the treatment of chronic asthma to improve
patient compliance, bioavailability and reduce the inter-subject variability.
ª 2011 Cairo University. Production and hosting by Elsevier B.V. All rights reserved.
Introduction
The transdermal route of administration has been recognized
as one of the highly potential routes. It has the advantages
of obviating drug metabolism or chemical degradation in the
gastrointestinal tract as well as the hepatic ﬁrst-pass effect
[1,2]. Transdermal delivery has the potential for highly pro-
longed and controlled drug delivery. In many cases, delivery
can be interrupted when it is desired [3].
On the other hand, the main limitation of transdermal
delivery of drugs is that the skin layers provide a great resis-
tance to the penetrant molecules. To overcome these limita-
tions, different strategies have been developed to minimize
the skin’s barrier function, such as employing appropriate
components, skin enhancer [4] or applying electricity or ultra-
sound [5] to facilitate the penetration of drugs.
Fenoterol is a selective b2-adrenoreceptor agonist with
effect on smooth and skeletal muscles, which include bron-
chodilation, relaxation of the uterus. It is structurally re-
lated to orciprenaline and terbutaline but is more selective
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than the parent drug for b2-receptors. It has a longer dura-
tion of action than isoprenaline and has a less side effect on
the heart rate [6]. A transdermal dosage form (TDD) of
fenoterol may be quite useful in the treatment of chronic
asthma and the reversible element of airway obstruction
commonly found in chronic obstruction airways disease
(COAD).
The development of a transdermal dosage form for feno-
terol can be based on its pharmacokinetic properties, i.e. the
short half-life and incomplete absorption from the gastrointes-
tinal tract due to its ﬁrst pass metabolism. Only 14% and 9%
of fenoterol were absorbed after nasal and pulmonary admin-
istration, respectively [7].
A 2.5 mg oral dose provides bronchodilatation for about
6 h which may not be sufﬁcient to prevent nocturnal wheezing.
A sustained release fenoterol microsphere was formulated by
Lin et al. [8].
In the light above, the objective of this paper was to develop
a transdermal formulation for the delivery of fenoterol.
Experimental
Materials
Fenoterol, cis-oleic acid and dimethyl sulphoxide (DMSO)
were purchased from Sigma (St. Louis, Mo, USA). Transcu-
tol (Gattefoss, St. Priest, France). Propylene glycol was ob-
tained from Fisher scientiﬁc (Fair Lawn, NJ, USA).
Polyethylene glycol 300 NF was provided by Union Carbide
Chemicals (Danbury, CT, USA). (R)-(+)-limonene, (R)-()-
carvone, cineole, a-pinene and 1-dodecyl-2-pyrrolidinone were
purchased from Aldrich chemical company (Milwaukee, WI,
USA). Duro-Tak 87-2074 was purchased from National
Starch and Chemical Company (Bridgewater, NJ, USA).
Scotchpak polyester multilam ﬁlm 1006 with 2.84 mm thick-
ness and Scotchpak 1022 release liner with 3 mm thickness
from 3 M (St. Paul, MN, USA).
Animal models
Male hairless Guinea pig 8–10-week-old of 400 g weight ob-
tained from Charles River laboratories (MA, USA). The study
protocol was reviewed and approved by the Institutional
Animal care and use Committee IACUC (University of Rhode
Island, Kingston, RI, USA).
High performance liquid chromatography
A water liquid chromatography (Waters associates, Milford,
MA, USA) was equipped with an automated gradient sampler
controller, model 717 plus auto sampler, model 515 HPLC
pump, model 480 LC spectrophotometer and model 746 data
module integrator. The column used was supelcosil LC-18-
DB (5 lm, 4.6 · 250 mm) and the mobile phase consisted of
0.01 M potassium dihydrogen phosphate adjusted to pH 6.5
and methanol (30:70). The absorbance wavelength was set to
231 nm.
Determination of fenoterol saturated solubility in different
solvents or co-solvents systems
The saturated solubility of fenoterol in a variety of solvents
viz. water, transcutol, polyethylene glycol 300 (PEG 300), pro-
pylene glycol (PG), dimethyl sulfoxide (DMSO), dimethyl iso-
sorbide (DMI), ethyl acetate and oleic acid was determined in
triplicate at room temperature of 25 C. In addition, fenoterol
solubility was determined in co-solvents viz. 90% propylene
glycol in isotonic phosphate buffer (pH 7.4), 10% PG in iso-
tonic phosphate buffer (pH 7.4), dimethyl isosorbide/transcu-
tol (1:1) ratio and oleic acid/transcutol (1:1) ratio. An excess
amount of fenoterol was suspended in different media in
tightly closed screw cap vials equilibrated in a rotating bottle
for 24 h. Then, an aliquot of the suspensions was transferred
to a 1-ml microcentrifuge ﬁlter, ﬁtted with a 0.22 lm nylon ﬁl-
ter (Corning Incorporated, Corning, NY, USA), and centri-
fuged. The ﬁltrates were appropriately diluted with methanol
before assaying by HPLC.
Preparation of different fenoterol liquid systems
Different fenoterol liquid systems were prepared by dissolving
or suspending 40 mg/ml of fenoterol in different solvents such
as polyethylene glycol 300, propylene glycol, transcutol, a mix-
ture of 90% v/v and 10% v/v of propylene glycol in isotonic
phosphate buffer of pH 7.4 or in co-solvent systems formed
from transcutol/dimethyl isosorbide (1:1) and transcutol/oleic
acid of the same ratio.
Physicochemical investigation of the interaction
DSC analysis was carried out on pure substances (fenoterol
and Duro-Tak adhesive) and their physical mixtures. Ther-
mograms were performed using a Perkin Elmer DSC7 system
equipped with a computerized data station. All samples (5 mg)
were weighed and heated at scanning rate of 10 C/min be-
tween 30 and 300 C. The measurements were performed in
triplicate.
Preparation of fenoterol patches with different drug
concentration
Prototype patches were prepared by using a lab hand coater.
The calculated amount of fenoterol was weighed and dispersed
in oleic acid. The drug/oleic acid dispersion was then mixed
with Duro-Tak containing 28% total solids as a selected
adhesive in a ratio of 1:9 inside a screw-cap bottle having a
hole at the center of the cap. Samples with different drug con-
centrations 2%, 5%, 9% and 12% (w/w) were mixed with stir-
rer (Cole Parmer instrument Co., Chicago, IL) equipped with
an appropriate size propeller at 100 rpm for 1 h. Following
drug mixing the drug/adhesive solutions were casted using a
lab-hand coater adjusted at clearance of 500 lm onto a Scotch-
pak 1022 release liner (3M, St. Paul, MN), left overnight and
then, cured at 65 C for half an hour, then the laminate was
covered with a heat seable Scotchpak packing polyester ﬁlm
1006 (3M, St. Paul, MN) and kept in the dark at room temper-
ature until use. In all the above prepared patches 10% (v/v)
oleic acid in Duro-Tak adhesive was used.
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Cis-oleic acid in a concentration of 10% v/v was also tried
instead of oleic acid and was included in the 12% (w/w) feno-
terol patch with the same above procedures.
Effect of the skin pretreatment with oleic acid on fenoterol
permeation
Pretreatment of the skin with 25 ll oleic acid 2 h before
patches application was also tested to evaluate the drug perme-
ation with and without pretreatment with oleic acid.
Preparation of fenoterol transdermal patches using different
enhancers
Different enhancers were tested instead of oleic acid as carv-
one, a-pinene, cineole, limonene, dimethyl sulfoxide (DMSO),
dimethyl isosorbide (DMI) and dodecyl pyrolidinone (DPY)
which is one of the azone derivative. Preparations of transder-
mal patches proceeded as previously discussed except that the
10% (v/v) oleic acid was replaced by 10% from the different
selected enhancers with Duro-Tak adhesive. Control patch
was also fabricated using 12% (w/w) drug in adhesive only
without oleic acid or any other enhancer.
Permeation study of fenoterol through hairless guinea pig skin
Guinea pigs were injected by pentobarbital sodium till sacri-
ﬁced and the full thickness abdominal and dorsal skin was ex-
cised. Skin was slowly thawed and was cut into small circular
pieces of 2.5 cm diameter. The lower surface of the skin was al-
lowed to hydrate for 1 h at 37 C prior to experimentation.
The permeation of fenoterol was studied using ﬂat ﬂange
Franz diffusion cells. The membrane was mounted carefully
onto the diffusion cell with the stratum corneum side facing
the donor compartment. The receiver buffer was de-aerated
before use with a sonicator ﬁtted with vacuum pump.
Volumes of 150 ll of the tested liquid systems under inves-
tigation containing 6 mg fenoterol were placed in the donor
chamber and covered with a rubber plug. The active diffusion
area was 0.64 cm2.
For permeation study from the transdermal patches, the
same procedure as in liquid formulation were done except
the patches were cut into pieces of 2.5 cm diameter and applied
to the skin instead of the liquid formulation. Pretreatment of
the skin with 25 ll oleic acid 2 h before patches application
was also tested to evaluate the drug permeation with and with-
out pretreatment with oleic acid.
Finally, the receptor solution was completely withdrawn
after 4, 12, 24, 36 and 48 h. The fenoterol concentration was
determined using HPLC. Each experiment was performed in
six replicates.
Data analysis
The cumulative amounts of fenoterol penetrating per unit skin
area (Q) were plotted against time. From the slope of the linear
portion of the plot a steady state ﬂux (SSF) was determined.
The permeability coefﬁcient (Kp) was calculated as the ratio
of SSF and the critical concentration of fenoterol in the for-
mula. Lag time (tlag) was estimated by extrapolation of the lin-
ear portion of the plot to the time axis. The cumulative amount
of drug permeated per unit area (Q24) obtained for various
formulae was compared using a one-way ANOVA test fol-
lowed by Fisher’s least signiﬁcant test. Differences between
the treatments were assumed to be signiﬁcant at p< 0.05.
All data analysis and statistical calculations were performed
using Stat view Statistical Software 4.57 for Windows (CA,
USA).
Results and discussion
Fenoterol solubility in different solvents
It was observed from Table 1 that, the highest fenoterol solu-
bility was given in dimethyl sulfoxide (DMSO) which was
amounted to be 170.2 mg/ml. However, lower drug solubility
was recorded in solvents having moderate polarity like propyl-
ene glycol (136 mg/ml), polyethylene glycol 300 (118.5 mg/ml)
and transcutol (103 mg/ml). On the other hand, on increasing
the buffer percent mixed with propylene glycol, a decrease in
fenoterol solubility was observed as given with 90% of propyl-
ene glycol in isotonic phosphate buffer (97.96 mg/ml) and 10%
of propylene glycol in the same buffer (70.28 mg/ml). Transcu-
tol co-solvent with dimethyl isosorbide (DMI) increased drug
solubility from 9.05 mg/ml in DMI alone to 39.43 mg/ml in
the mixture while, transcutol mixture with oleic acid increased
drug solubility from 0.028 mg/ml in oleic acid alone to
8.68 mg/ml in the mixture. However, a limited solubility of
the drug was watched in ethyl acetate (0.07 mg/ml). The vari-
ability in drug solubility would depend upon the dielectric con-
stant of the tried solvents or co-solvents.
Effect of vehicles type on the skin permeation of fenoterol
The cumulative amount of fenoterol permeated through hair-
less guinea pig skin from different liquid systems was compiled
in Table 2 and graphically represented in Fig. 1. It was obvious
that, the highest drug permeation observed after 24 h was
reached with the system composed of 10% propylene glycol
(PG) in phosphate buffer compared to each of PG, 90% PG
in phosphate buffer and polyethylene glycol 300 (PEG 300).
These vehicles could be arranged in an ascending order in rela-
tion to the cumulative amount of drug permeated as follows:
PEG 300, PG, 90% PG in phosphate buffer and 10% PG in
the same buffer. On the other hand, transcutol as a pure vehi-
cle did not show a signiﬁcant drug permeation except after
36 h which was very low compared with its mixtures with di-
Table 1 Solubility study of fenoterol in different solvents.
Solvent type Solubility mg/ml ± SD
Water 61.45 ± 3.65
Transcutol 103.0 ± 8.97
PEG 300 118.5 ± 11.23
Propylene glycol 136.0 ± 13.23
Dimethyl sulfoxide (DMSO) 170.2 ± 19.68
Ethyl acetate 0.07 ± 0.015
Dimethyl isosorbide (DMI) 9.05 ± 1.24
Oleic acid 0.0284 ± 0.009
90% PG in Buﬀer 97.96 ± 19.4
10% PG in Buﬀer 70.28 ± 12.48
DMI/Transcutol (1:1) 39.43 ± 13.72
Oleic acid/Transcutol (1:1) 8.68 ± 4.49
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methyl isosorbide in 1:1 ratio and transcutol: oleic acid with
the same ratio. However, the tried transcutol or its mixtures
with dimethyl isosorbide and oleic acid at 1:1 ratio exhibited
a drug permeation proﬁle that could be arranged in an ascend-
ing order as such: transcutol, transcutol: dimethyl isosorbide
mixture and transcutol: oleic acid mixture.
It was remarkable that, the higher the drug solubility in
each of pure propylene glycol, transcutol and polyethylene gly-
col 300, the lower the drug permeation through animal skin
quantiﬁed as cumulative amounts of drug permeated after
24 h (Q24). However, blends of 90% and 10% propylene glycol
with phosphate buffer showed a noticeable increase in the
cumulative amounts of the drug permeated after 24 h (Q24).
Furthermore a high extent of drug permeation was recorded
with blends of transcutol/ dimethyl isosorbide and transcutol/
oleic acid at 1:1 ratio where the latter showed the highest value
(2004.04 lg cm2) compared with others. It was obvious as
well that, transcutol: oleic acid mixture was shown to be
approximately ten times more effective than 10% PG in buffer
with regard to the cumulative amount of fenoterol permeated
after 24 h (Q24).
With relation to the permeability coefﬁcients of fenoterol in
the tested liquid preparations shown in Table 2, it was obvious
that, the highest reached permeability coefﬁcient of fenoterol
was shown by transcutol/oleic acid mixture in 1:1 ratio that
amounted to be 774.3 cm h1 · 103. The latter ﬁnding would
indicate the superiority of drug diffusivity when placed in tran-
scutol/ oleic acid mixture of 1:1 ratio as measured by Q24, SSF
and permeability coefﬁcient. This ﬁnding might be attributed
to the excellent solubilizing power of transcutol for fenoterol
in oleic acid which aided the diffusivity of the drug in this sys-
tem. Also, the increased permeation parameters of fenoterol
from transcutol–oleic acid binary mixture might be explained
by the limited solubility of fenoterol in oleic acid that is
amounted to be 0.028 mg/ml [9–11]. Almirall et al. [9] noticed
that, increasing the drug solubility in the vehicle will lower its
thermodynamic activity in this vehicle and hence decreases the
drug permeation through the skin.
Furthermore, PG tried in 10% in isotonic phosphate buffer
showed higher value of (Q24) for fenoterol than 90% of the
same solvent because it was evident from the solubility study
that, the drug has a higher solubility in PG than water. Also,
higher percentage of water opens up the compact structure
of the horney layer [12].
Differential scanning calorimetry of fenoterol and its physical
mixture with adhesive
The DSC thermograms (ﬁgure not shown) of fenoterol and
Duro-Tak declared that, fenoterol exhibited an exothermic
peak at 240.39 C while Duro-Tak declared an exothermic
peak at 91.95 C. The physical mixture consisting of fenoterol:
Duro-Tak with 1:1 ratio showed the aforementioned original
peaks with no evidence of any interaction between the drug
and the adhesive.
Effect of fenoterol concentration on its permeation through
hairless guinea pig skin
The inﬂuence of different fenoterol concentrations viz., 2%,
5%, 9% and 12% on its permeation across hairless guinea
pig skin was shown in Table 3 and graphically represented in
Fig. 2. It was obvious that, the cumulative amount of fenoterol
permeated per unit area after 24 h showed a gradual increase
upon increasing drug concentration, where, 12% of fenoterol
in a matrix composed of 10% oleic acid or cis-oleic acid with
90% Duro-tak exhibited the highest values.
It was noteworthy that, the use of 12% of fenoterol to-
gether with 10% of cis-oleic acid instead of oleic acid apprecia-
bly increased Q24, steady state ﬂux and permeability coefﬁcient
Table 2 Permeation parameters of different fenoterol liquid systems through guinea pig skin.
Liquid formulae SSF lg cm2 h1 ± SD Q24 lg cm
2 ± SD tlag h Permeability coeﬃcient cm h
1 · 103 r2*
PEG 300 n= 5 0.257 ± 0.103 11.6 ± 8.9 0.44 0.042 0.9924
PG n= 4 0.338 ± 0.224 22.82 ± 11.11 0.989 0.056 0.948
Transcutol n= 4 0.13 ± 0.08 13.37 ± 8.92 0.436 0.021 0.9967
90% PG n= 4 14.319 ± 13.72 65.81 ± 45.43 1.824 2.386 0.9904
10% PG n= 4 9.191 ± 6.8 202.79 ± 46.78 0.391 1.53 0.9939
Transcutol:DMI n= 5 340.37 ± 88.0 262.496 ± 119.8 3.261 56.72 0.9237
Transcutol:Oleic acid n= 6 4645.76 ± 528.0 2004.04 ± 386.82 0.669 774.29 0.9915
All formulas between the same parentheses are not signiﬁcantly different from each other in the Q24 data but differ signiﬁcantly from those
included in other (P< 0.0001).
(PEG 300, PG, Transcutol, 90% PG, 105PG), (Transcutol:DMI), (Transcutol:Oleic acid).
* The r2 describes only the linear portion in the graphs.
Fig. 1 Permeation of fenoterol from different liquid formulation
through guinea pig skin.
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but without variability in the lag time value. This would indi-
cate the permeation beneﬁt of cis-oleic acid over oleic acid.
This ﬁnding could be attributed to the higher ability of cis-
oleic acid to penetrate the skin in a faster way rather than
normal oleic acid and this may be due to the lower hindrance
effect of its chemical structure.
Effect of skin pretreatment with oleic acid on fenoterol
permeation
It was obvious from Table 4 and Fig. 3 that, the pretreatment
of guinea pig skin with oleic acid resulted in a remarkable in-
crease in drug permeation in terms of Q24 all over the different
drug concentrations in patches compared with the untreated
skin shown in Table 3. The highest extent of drug permeation
occurred as a result of pretreatment of guinea pig skin with
oleic acid was recorded with 2% fenoterol patches which was
double the quantity of Q24 without treatment.
One way to increase drug penetration is to pre-treat the skin
with the enhancers before drug application. Another possibil-
ity is to add the enhancer to the drug formulation, but this may
prolong the lag time of drug penetration depending on the par-
titioning delay and the subsequent effect of the enhancer in the
skin [13].
Table 3 Permeation parameters of fenoterol transdermal patches using different drug concentrations through guinea pig skin.
Drug Conc. SSF lg cm2 h1 ± SD Q24 lg cm
2 ± SD tlag h Permeability coeﬃcient cm h
1 · 103 r2*
2% in oleic acid n= 6 2.438 ± .083 8.29 ± 3.48 8.59 1.52 0.9999
5% in oleic acid n= 6 35.05 ± 6.47 21.74 ± 8.0 11.5 21.9 0.9990
9% in oleic acid n= 6 141 ± 23.68 45.64 ± 20.81 10.88 88.12 0.9920
12% in oleic acid n= 5 1191 ± 20.4 247.34 ± 55.9 5.74 744.37 0.9915
12% in cis-oleic acid n= 6 1435.7 ± 48.88 266.459 ± 87.78 5.86 897.31 0.9900
All formulas between the same parentheses are not signiﬁcantly different from each other in the Q24 data but differ signiﬁcantly from those
included in other. (P< 0.0001).
(2%, 5% and 9% in oleic acid), (12% in oleic acid, 12% in cis-oleic acid).
* The r2 describes only the linear portion in the graphs.
Table 4 Permeation parameters of fenoterol transdermal patches after guinea pig skin treatment with oleic acid using different drug
concentrations.
Drug Conc. SSF lg cm2 h1 ± SD Q24 lg cm
2 ± SD tlag h Permeability coeﬃcient cm h
1 · 103 r2*
2% in oleic acid n= 6 7.72 ± 0.078 16.26 ± 4.33 7.26 4.825 0.9913
5% in oleic acid n= 6 44.09 ± 1.22 26.92 ± 6.95 10.088 27.55 0.9923
9% in oleic acid n= 6 49.88 ± 0.189 75.3 ± 5.96 3.516 31.175 0.9957
12% in oleic acid n= 6 1627.3 ± 48.75 255.19 ± 9.73 7.17 1017.06 0.9999
12% in cis-oleic acid n= 6 1901.8 ± 64.78 285.88 ± 35.47 6.6 1188.6 0.9979
All formulas between the same parentheses are not signiﬁcantly different from each other in the Q24 data but differ signiﬁcantly from those
included in other (P< 0.0001).
(2% and 5% in oleic acid), (9% in oleic acid), (12% in oleic acid), (12% in cis-oleic acid).
* The r2 describes only the linear portion in the graphs.
Fig. 3 Permeation of fenoterol from different concentration
patches after pretreatment the skin with oleic acid.Fig. 2 Permeation of fenoterol from different concentration
patches.
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The enhancing effect of oleic acid on fenoterol permeation
went parallel with that recorded with Cooper and Williams
[14–17], who mentioned that, fatty acids like oleic acid are
known to have a potent skin permeation enhancing effect
when used alone or in combination with glycols. The perme-
ation enhancing effect of oleic acid could be attributed to the
disruption of the lipid bi-layer that is ﬁlling the extra-cellular
spaces of stratum corneum.
Barry [18] and Kin [19] postulated that oleic acid increases
the ﬂuidity of skin liquid while Ongpipattanakul et al. [20]
mentioned that, oleic acid forms a ﬂuid phase within the stra-
tum corneum which enhances drug permeation.
Effect of different enhancers on fenoterol permeation from
transdermal patches
The permeation parameters reached by mathematical calcula-
tions are compiled in Table 5 and Fig. 4. It was obvious that,
12% of fenoterol patches in a matrix of Duro-tak containing
10% of carvone as permeation enhancer diminished the extent
of fenoterol permeation quantiﬁed as Q24 by almost 40% in
comparison with control patches. Furthermore, a pronounced
decrease in steady state ﬂux, lag time and permeability coefﬁ-
cient were observed which went parallel with the diminishing
in drug diffusion.
On the other hand, the incorporation of 10% of a-pinene,
cineole and limonene in fenoterol-Duro-tak patches improved
the extent of drug permeability (Q24) where, limonene was the
highest (17.62 lg cm2) and a-pinene was the lowest
(10.09 lg cm2) in this regard. However, there was a decrease
in the steady state ﬂux as well as the lag time and the perme-
ability coefﬁcient for patches containing a-pinene compared
with the control patches.
Jain et al. [21] suggested that the main barrier or the rate
limiting step in transdermal drug delivery of polar, water sol-
uble drugs is the lipophilic part of subcutaneous layer in which
lipids (ceramides) are arranged in a bilayer. Ceramides are
tightly packed in the bilayer due to the high degree of hydro-
gen bonding. The amide group of ceramide is hydrogen
bonded to amide group of another ceramide and a tight net-
work of hydrogen bonding is formed at the head of ceramides.
This hydrogen bonding provides strength and stability to lipid
bilayer and imparts the barrier property to the subcutaneous
layers.
Recently; it has been proved that amide 1 of ceramide 5 is
laterally hydrogen bonded between head of ceramides [22].
Cineole has a greater enhancing effect than carvone because
the boiling point of cineole is 173 C which is less than carvone
(230 C) indicating that cineole has a weak cohesion or self
association than carvone [23]. So, the oxygen of functional
ether in cineole is in free form for interaction facilitating
hydrogen bond formation. Therefore, the energy required for
competitive hydrogen bonding in skin ceramides is relatively
Table 5 Permeation parameters of 12% fenoterol transdermal patches using 10% concentration of different enhancers through
guinea pig skin.
Drug Conc. SSF lg cm2
h1 ± SD
Q24 lg
cm2 ± SD
tlag h Permeability
coeﬃcient.
cm h1 · 103
r2*** Enhancement
Ratio (ER)
Q24
(R)-()-Carvone n= 6 0.312 ± 0.02 6.12 ± 3.1 3.65 0.195 1 0.63
a-Pinene n= 5 3.6 ± 0.2 10.09 ± 7.8 7.85 2.25 0.9800 1.05
Plain Duro-tak (control)
n= 3
13.95 ± 2.6 9.6 ± 3.76 11.83 8.71 0.9764 Control
Cineole n= 4 48.94 ± 0.5 15.97 ± 4.5 15.64 30.58 0.9940 1.66
(R)-(+)-Limonene n= 4 77.5 ± 27.2 17.62 ± 13.3 16.27 48.43 0.9980 1.83
DMSO* n= 3 39.99 ± 17.1 31.4 ± 10.05 8.6 24.99 0.9979 3.27
DMI** n= 4 123.17 ± 1.7 57.06 ± 17.6 8.7 76.98 0.9999 5.94
Oleic acid n= 5 1191 ± 20.4 247.34 ± 55.9 5.74 744.375 0.9915 25.76
Cis-oleic acid n= 6 1435.7 ± 48.8 266.45 ± 87.7 5.86 897.31 0.9900 27.75
1-Dodecyl-2-pyrrolidinone n= 6 951.64 ± 9.2 404.69 ± 133.3 2.64 594.77 1 42.15
All formulas between the same parentheses are not signiﬁcantly different from each other in the Q24 data but differ signiﬁcantly from those
included in other. (P < 0.0001).
(Carvone, pinene, cineole, limonene, DMSO, DMI), (Oleic acid, cis-Oleic acid), (1-dodecyl-2-pyrrolidinone).
* Dimethyl sulfoxide.
** Dimethyl isosorbide.
*** The r2 describes only the linear portion in the graphs.
Fig. 4 Permeation of fenoterol from patches using 10% different
enhancers.
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less for cineole than carvone. On the other hand, in case of
carvone, additional energy is required to free the respective
functional group from strong self-association, as reﬂected by
higher boiling point. It has been reported that a-pinene and
limonene caused a shift in transition temperature of the skin
[16,24]. In other words, limonene is not able to break the
hydrogen bond network between ceramides due to absence
of a hydrogen bond accepting or donating group.
Pertaining to the inﬂuence of non-terpene type enhancers in
10% concentration viz., dimethyl sulfoxide (DMSO), dimethyl
isosorbide (DMI), oleic acid, cis-oleic acid and 1-dodecyl-2-
pyrolidinone (DPY), it was obvious from Table 5 that, all of
them improved the drug permeation through hairless guinea
pig skin compared to the plain patch.
Table 5 shows the extent of drug permeation in terms of the
cumulative amount of fenoterol permeated in 24 h (Q24) where,
the greatest enhancement of drug permeation was achieved by
the DPY (404.69 lg. cm2) while the lowest value was given by
DMSO (31.4 lg cm2).
The permeation enhancement offered by 1-dodecyl-2-pyro-
lidinone (DPY) was shown to be 40 times as effective as the
control patches without enhancer and 12 times as effective as
Duro-tak patches containing 10% DMSO as an enhancer.
On the other hand, it was evident from Table 5 that, the
steady state ﬂux and the permeability coefﬁcients were in-
creased to an appreciable extent upon the inclusion of 10%
of each of DMSO, DMI, oleic acid and cis-oleic acid. However,
1-dodecyl-2-pyrolidinone (DPY) showed a lower extent of stea-
dy state ﬂux than oleic and cis-oleic acid only. Furthermore, the
implication of the aforementioned enhancers in the drug
patches in 10% concentrations resulted in shortening the lag
time of the drug permeation where, the lowest value (2.64 h)
was given by 1-dodecyl-2-pyrolidinone. This would indicate a
greater rapidity in drug permeation in presence of all the tried
enhancers where, DPY superseded the others in this regard.
In conclusion, 1-dodecyl-2-pyrolidinone (DPY) in 10%
concentration showed the highest enhancement ratio com-
pared with the other tried enhancers while, DMSO showed
the lowest value compared with others in 10% concentration.
It is worthnoting that, 1-dodecyl-2-pyrolidinone (DPY) in
10% concentration showed the highest Q24 and the shortest
lag time among the all tested terpenes or non-terpenes enhanc-
ers in 10% concentration.
Menczel et al. [25] suggested that, dimethyl sulfoxide
(DMSO) and dimethyl isosorbide (DMI) disrupt stratum cor-
neum lipid organization, making it permeable. The essential
action increases the drug diffusion coefﬁcient. The accelerant
molecules jump into the bilayer, rotating, vibrating and trans-
locating forming micro cavities and increasing the free volume
available for drug diffusion.
As discussed before, fatty acids like oleic acid are known to
have a potent skin permeation enhancing effect when used
alone or in combination with glycols [15,26].
These effects appear to involve the disruption of lipid bi-
layer that is ﬁlling the extra cellular spaces of stratum cor-
neum. It has been postulated to act by increasing the ﬂuidity
of skin liquid [18,19] and by forming a ﬂuid phase within the
stratum corneum [20].
As concluded from the previous results, it is obvious that
cis-oleic acid has more enhancing effect than oleic acid and this
can be explained to the higher ability of cis-oleic acid to pene-
trate the skin rather than normal oleic acid and this may be
due to less hindrance effect of the chemical structure of cis-
oleic acid.
From the previous results, DPY was shown to be a superior
enhancer over all tested enhancers showed the shortest lag time
that amounted to be 2.64 h and the highest enhancement ratios.
The superiority of DPY as permeation enhancer might be
attributed to its nature as being azone derivative. The ring size
of the lactam derivative increased the enhancer activity. A di-
rect trend between ring size and permeability coefﬁcient was
identiﬁed. DPY which is ﬁve membered lactam moieties
showed greater transdermal enhancement activity compared
to the 6- and 7-membered (azone) lactam moieties [27].
Several authors have investigated Azone analogues and
have shown that pyrolidinone and piperidinone analogues in-
crease percutaneous absorption of various drugs [28,29].
Conclusion
In conclusion, 1-dodecyl-2-pyrrolidnon (DPY) was shown to
be exclusively the best enhancer for fenoterol when tried in
10% concentration. Also, carvone was shown to be the worst
enhancer for drug permeation since it diminished the drug per-
meation when tried in 10% concentration compared with the
control Duro-tak patches.
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